MedTrace Logo

Preparation of Patients for Cardiac Surgery

NCT00906646 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 117

Last updated 2009-05-21

No results posted yet for this study

Summary

This was a prospective randomised trial of metabolic therapy including antioxidants and cellular energisers to determine whether this therapy could improve the results of cardiac surgery. The hypothesis was that the metabolic therapy could improve clinical recovery.

Conditions

  • Coronary Artery Bypass Graft Surgery
  • Cardiac Valve Surgery

Interventions

DIETARY_SUPPLEMENT

Metabolic therapy

Coenzyme Q10 - 100 mg tds Magnesium orotate - 400 mg tds Lipoic acid - 100 mg tds Omega-3 fatty acids - 300 mg (in 1 g fish oils) tds Selenium - 200 µg

DIETARY_SUPPLEMENT

Placebo

Placebo tablets

Sponsors & Collaborators

  • Griffith University

    collaborator OTHER

  • Bayside Health

    lead OTHER_GOV

Principal Investigators

  • Franklin L Rosenfeldt, MBBS, MD · The Alfred

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2006-06-30
Completion
2008-12-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00906646 on ClinicalTrials.gov